Cholamandalam Investment Q4 Review - Beefing-Up Buffer To Cushion Earnings: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
- Cholamandalam Investment and Finance Company Ltd.’s Q4 FY21 earnings surprised on few counts:
- Despite retracement in collection efficiency, stage-II/III went up QoQ (crossing 10% mark); however restructuring of ~2% was categorised as stage-II assets.
- Its stance of creating further Covid-19 buffer of Rs 3.5 billion (against its Q3 FY21 guidance of consuming the buffer).
- Elevated employee cost of Rs 2.7 billion (versus Rs 1.6 billion quarterly run-rate).
What helped offset this drag was sustained business momentum (14% assets under management growth) and consistently declining funding cost.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.